Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion
from JAMA Oncology
In this randomized clinical trial of 247 patients, those receiving sorafenib plus hepatic arterial infusion chemotherapy had a significantly longer median overall survival time (13.37 vs 7.13 months) and acceptable safety profiles compared with patients receiving sorafenib. First-line sorafenib plus hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma and portal vein invasion improved survival compared with sorafenib alone.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063